Trial tests new combination of drugs to treat tuberculosisBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2216 (Published 20 March 2012) Cite this as: BMJ 2012;344:e2216
- Bob Roehr
- 1Washington, DC
The Global Alliance for TB Drug Development (TB Alliance) has launched a first of its kind clinical trial of a new drug combination that is enrolling patients with drug sensitive or multidrug resistant tuberculosis.
The trial is a milestone in the process of revitalising all phases of tuberculosis research—from basic pathology to diagnostics, new drugs, and vaccines—that began a decade ago, said Mel Spigelman, president of the TB Alliance, at a forum in Washington, DC, in advance of world TB day on 24 March. The alliance is a collaboration of drug companies, government agencies, and charities.
To elicit a response in people with drug resistant tuberculosis, doctors have often added a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial